MyImmune

AbSapien uses AI to find human antibodies among billions of B cell receptor sequences, selected in the human immune system rather than engineered.

MyImmune uses AI for patient stratification and predictive biomarkers to reduce clinical trial risks and extend exclusivity.

MyImmune’s platform converts NGS data into AI predictive biomarkers, reducing clinical trial risks while retaining sample custody.

MyImmune analyzes the adaptive immune repertoire to improve the probability of technical and regulatory success and optimize capital efficiency.

Dive into the marvels of modern innovation, where the only constant is change. A journey where pixels and data converge to craft the future.

MyImmune’s AI decodes the immune system to improve therapies, reduce immunology asset risks, detect diseases, and identify optimal treatments.

MyImmune’s AI decodes the immune system to improve therapies, reduce immunology asset risks, detect diseases, and identify optimal treatments.

MyImmune Inc. provides its imprint with company details, registered address, and representative information for contact via an online form.

MyImmune outlines terms and conditions for using its diagnostic platform and website, detailing user rights and obligations.

Five startups from s'more works’ Japan-based **Constellation program** advance into **MassChallenge’s 2026 Traction Program**, transitioning from early-stage exploration to hands-on market engagement. The selected founders will participate in programming across **Boston and Dallas**, leveraging resources to accelerate real-world business development. This partnership expands MassChallenge’s global footprint while providing targeted support for scaling ventures.

Apr 2026MassChallenge - MassChallenge is the global network for innovators working to solve massive challenges.News article

MassChallenge and Smore Works have selected **10 Japanese startups** as finalists for the **2025 Constellation Program**, designed to help them expand into the U.S. market. The initiative accelerates innovation-driven companies by providing resources and networking opportunities. This program targets high-potential startups aiming to scale globally through strategic U.S. market entry.

Jul 2025MassChallenge - MassChallenge is the global network for innovators working to solve massive challenges.News article

Osaka University presents its DeepTech Showcase at the Japan Innovation Campus in Palo Alto, demonstrating efforts to commercialize lab research. The event, supported by the Consulate-General of Japan in San Francisco, highlights collaborations with the Japan Society of Northern California (JSNC) and JETRO. Researchers showcase solutions aimed at generating societal and economic impact through innovation.

Dec 2024sf.us.emb-japan.go.jpNews article

MyImmune raises pre-seed funding to advance its AI-driven platform for diagnostics and therapeutics. The company focuses on integrating artificial intelligence into medical tools for disease detection and treatment solutions. The investment will support further development and scaling of its technology pipeline.

Oct 2024openPR.comNews article